Capricor Therapeutics Inc. (CAPR) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, CAPR scores 34 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 8/20 (ROIC -35%; FCF yield -18.86%), Whale 13F Flow at 4/20 (institutional accumulation and options positioning), Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 7/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 12/20 (Altman Z 3.38; Piotroski F 2/9; Debt/Equity 0.5). The weakest pillars are Insider Conviction and Whale 13F Flow, which together indicate limited observable sponsorship from insiders and large institutions. The cash-engine pillar reflects negative return on invested capital and negative free-cash-flow yield, meaning the business is not currently generating returns on capital in the source data. The balance-sheet pillar is the strongest relative score, supported by a 3.38 Altman Z-Score, but the Piotroski F-Score of 2/9 signals weak fundamental quality. For a prospective investor, the rating frames the stock as high-risk on the current evidence. Potential upside drivers in the news flow (such as the November FDA decision referenced in the news wire) are event-dependent and are not quantified in the source data, while valuation tradeoffs are difficult to assess because P/E and EPS are unavailable.

Capricor Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. Per the profile, the company has a market capitalization of $0.4B. The source data does not specify its products, customers, or revenue model beyond reported revenue figures in the SEC financials. Revenue is reported as $0.0M for FY 2025, $22.3M for FY 2024, and $25.2M for FY 2023.

Per the SEC financials, operating losses widened from $-24.1M in FY 2023 to $-108.1M in FY 2025, and revenue declined to $0.0M in FY 2025. Gross, operating, and net margins are each reported as 0% in the market data. Per the Roarable RQD rating, ROIC is -35% and the Altman Z-Score is 3.38, while the Piotroski F-Score is 2/9 and Debt/Equity is 0.5. Reported cash is $287.8M for FY 2025, compared with $11.3M for FY 2024. The source data does not provide a debt figure for any period.

Per the recent news and catalysts feed, the most prominent items are: a market-wire report of a near-5% stock rise tied to heart data for deramiocel ahead of a November FDA decision; a Seeking Alpha report referencing HOPE-3 open-label extension data for Duchenne muscular dystrophy; a Benzinga report on Monday trading action; a GuruFocus report, flagged as a RISK WATCH item, describing a share drop of 10% despite positive data; a StockInvest.us forecast piece; and a TradingView estimates page. The clearest catalyst identified is the November FDA decision on deramiocel. The RISK WATCH item is the GuruFocus report of a 10% decline. The Butterfly Supply-Chain Graph reports no supply-chain links and no proprietary signals.

• What is the scope and timing of the November FDA decision on deramiocel, and what outcomes are possible?
• What are the company's current debt obligations, given that debt is reported as N/A in every period?
• What is the basis for the reported cash increase to $287.8M in FY 2025 against a $0.0M revenue year?
• What are the forward earnings or cash-flow expectations, given that P/E, EPS, and EV/EBITDA are unavailable?
• What supply-chain, partner, or manufacturing dependencies exist, given that the supply-chain graph reports none?